THE WHAT? The US Food and Drug Administration (FDA) has issued a warning letter to Revlon, citing failures in product safety testing and quality control procedures at the company’s manufacturing operations.
THE DETAILS In a warning letter dated June 2, the FDA said Revlon had not adequately tested certain products for potential contamination by a known human carcinogen, although the specific product and contaminant were redacted from the publicly released document. The agency also found that Revlon failed to verify the reliability of supplier testing methods, did not sufficiently test for multiple impurities, and allowed levels of yeast and mold that exceeded standard testing limits. The FDA has requested a comprehensive remediation plan and instructed Revlon to conduct risk assessments and recalls if contaminated products are identified. Revlon said it stands by the safety of its products and is working with regulators to address the concerns. The findings stem from an FDA records review of Revlon’s Oxford, North Carolina manufacturing facility, the company’s largest production site.
THE WHY? The warning highlights increasing regulatory scrutiny of product safety and manufacturing standards within the beauty and personal care sector, particularly following recent recalls involving contamination concerns. Failure to address the FDA’s findings could result in further enforcement actions, including restrictions on product exports and reputational damage for the company.
Source: Bloomberg
